Literature DB >> 23954451

Isoniazid prevention of HIV-associated tuberculosis.

Molebogeng Xheedha Rangaka1, Robert John Wilkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23954451     DOI： 10.1016/S1473-3099(13)70218-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

1.  Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.

Authors:  Johan van Griensven; Tesfa Simegn; Mengistu Endris; Ermias Diro
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

2.  Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial.

Authors:  L Mupfumi; B Makamure; M Chirehwa; T Sagonda; S Zinyowera; P Mason; J Z Metcalfe; R Mutetwa
Journal:  Open Forum Infect Dis       Date:  2014-06-25       Impact factor: 3.835

3.  A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study.

Authors:  Susan Shin-Jung Lee; Hsi-Hsun Lin; Hung-Chin Tsai; Ih-Jen Su; Chin-Hui Yang; Hsin-Yun Sun; Chien-Chin Hung; Cheng-Len Sy; Kuan-Sheng Wu; Jui-Kuang Chen; Yao-Shen Chen; Chi-Tai Fang
Journal:  PLoS One       Date:  2015-08-17       Impact factor: 3.240

4.  Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana.

Authors:  Lucy Mupfumi; Sikhulile Moyo; Kesaobaka Molebatsi; Prisca K Thami; Motswedi Anderson; Tuelo Mogashoa; Thato Iketleng; Joseph Makhema; Richard Marlink; Ishmael Kasvosve; Max Essex; Rosemary M Musonda; Simani Gaseitsiwe
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.